Experts' Perspectives: Advancements in Cardiomyopathy at ACC.24

In recent years, advancements in the treatment of cardiomyopathies have captivated the cardiology. However, experts and opinion leaders in cardiomyopathy are quick to remind others this progress was not overnight and comes as the result of tireless efforts by colleagues and their predecessors dating back decades.

In the last decade, a greater understanding of pathophysiology has given way to numerous advances in management, including the introduction of cardiac myosin inhibitors into treatment algorithms of patients with obstructive hypertrophic cardiomyopathy, such as mavacamten (Camzyos), which received approval for obstructive hypertrophic cardiomyopathy in April 2022. Now, the community looks ahead with anticipation to phase 3 data for a next-generation cardiac myosin inhibitor in aficamten.

Source: MDMag

To view the third party content, kindly click on the link below or read more. You will then leave this site and enter a third party site.